These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 10468696)

  • 41. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.
    Garsed K; Chernova J; Hastings M; Lam C; Marciani L; Singh G; Henry A; Hall I; Whorwell P; Spiller R
    Gut; 2014 Oct; 63(10):1617-25. PubMed ID: 24334242
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome.
    Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D
    Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alosetron and irritable bowel syndrome.
    Mayer EA; Bradesi S
    Expert Opin Pharmacother; 2003 Nov; 4(11):2089-98. PubMed ID: 14596662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial.
    Gunn D; Fried R; Lalani R; Farrin A; Holloway I; Morris T; Olivier C; Kearns R; Corsetti M; Scott M; Farmer A; Emmanuel A; Whorwell P; Yiannakou Y; Sanders D; Mclaughlin J; Kapur K; Eugenicos M; Akbar A; Trudgill N; Houghton L; Dinning PG; Ford AC; Aziz Q; Spiller R
    Trials; 2019 Aug; 20(1):517. PubMed ID: 31429811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.
    De Ponti F; Tonini M
    Drugs; 2001; 61(3):317-32. PubMed ID: 11293643
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.
    Whitehead WE; Duffy K; Sharpe J; Nabata T; Bruce M
    Aliment Pharmacol Ther; 2017 Jan; 45(1):14-26. PubMed ID: 27910150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients.
    Mangel AW; Chaturvedi P
    Digestion; 2008; 78(4):180-6. PubMed ID: 19092244
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
    Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW
    Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
    Berman SM; Chang L; Suyenobu B; Derbyshire SW; Stains J; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD; Mayer EA
    Gastroenterology; 2002 Oct; 123(4):969-77. PubMed ID: 12360456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
    Humphrey PP; Bountra C; Clayton N; Kozlowski K
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():31-8. PubMed ID: 10429738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of alosetron on the pharmacokinetics of fluoxetine.
    D'Souza DL; Dimmitt DC; Robbins DK; Nezamis J; Simms L; Koch KM
    J Clin Pharmacol; 2001 Apr; 41(4):455-8. PubMed ID: 11304903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
    Komoto S; Miura S
    Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
    Bush TG; Spencer NJ; Watters N; Sanders KM; Smith TK
    Am J Physiol Gastrointest Liver Physiol; 2001 Oct; 281(4):G974-83. PubMed ID: 11557518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
    Olden KW; Chey WD; Shringarpure R; Paul Nicandro J; Chuang E; Earnest DL
    Curr Med Res Opin; 2019 Mar; 35(3):461-472. PubMed ID: 30293448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome.
    Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ
    Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rifaximin therapy for patients with irritable bowel syndrome without constipation.
    Pimentel M; Lembo A; Chey WD; Zakko S; Ringel Y; Yu J; Mareya SM; Shaw AL; Bortey E; Forbes WP;
    N Engl J Med; 2011 Jan; 364(1):22-32. PubMed ID: 21208106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.